Financial

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 first quarter on Tuesday, May 12, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.

CVRx Announces Nomination of Michael Dale for Election to the Board of Directors

MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the nomination of Michael Dale to serve on its Board of Directors. Mr. Dale will stand for election at the annual meeting of stockholders scheduled for June 1, 2026.

Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease

CathWorks FFRangio® System employs drug-free, wire-free technology for comprehensive physiological assessment GALWAY, Ireland, April 20, 2026 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks,…

Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors

Milestones underscore clinical progress and strengthen commercial foundation LOS GATOS, Calif., April 8, 2026 /PRNewswire/ — Supira Medical, Inc. (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, today announced FDA approval to initiate the SUPPORT II Pivotal Trial. The trial is designed to support a future PMA submission and […]

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062 International dial in: 973-528-0011Access Code: 543818 Via online: A webcast of the call will be available on the Investor Relations section of the Company’s website at www.amarincorp.com.Access to the replay:Via telephone: Dial in within the United States: 877-481-4010International dial in: 919-882-2331Replay Code: 53836 Via online: A replay of the webcast will be accessible through the Investor Relations section of the Company’s website at www.amarincorp.com, beginning shortly after the end of the live call and available until 10/29/26. About AmarinAmarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD. Availability of Other Information About Amarin Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (http://www.amarincorp.com/investor-relations), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.  Amarin Contact InformationMedia Inquiries: Tegan Berry Amarin Corporation plc PR@amarincorp.com Investor Inquiries:Devin Sullivan & Conor RodriguezThe Equity Group on Behalf of Amarin dsullivan@theequitygroup.com or crodriguez@theequitygroup.com Investor.relations@amarincorp.com

Bunkerhill Health Secures CMS Reimbursement Pathway for AI Cardiovascular Analysis, Receives FDA Clearance for the First AI Algorithms to Evaluate Coronary and Aortic Valve Calcium on Contrast-Enhanced Chest CTs

SAN FRANCISCO–(BUSINESS WIRE)–Bunkerhill Health, an agentic AI company building healthcare’s system of action, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a new national billing code and associated payment under the Hospital Outpatient Prospective Payment System (OPPS) for algorithmic analysis of coronary artery calcium (CAC) and aortic valve calcium (AVC) on chest CT scans, effective April 1, 2026. The company also received U.S. Food and Drug Adm

Stereotaxis Announces Definitive Agreement to Acquire Robocath

ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions.

SCAI Reappoints JSCAI Founding Editor-in-Chief Alexandra J. Lansky, MD, MSCAI, for Second Term

WASHINGTON—The Society for Cardiovascular Angiography & Interventions (SCAI) today announced that Alexandra J. Lansky, MD, MSCAI, has been reappointed to a second five-year term as Editor-in-Chief of JSCAI, the official peer-reviewed journal of SCAI. SCAI launched JSCAI in 2022 as a fully digital platform to advance interventional cardiology research and practice, appointing Dr. […]